{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+of+Unknown+Primary", "query": { "condition": "Melanoma of Unknown Primary" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+of+Unknown+Primary&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:12:49.626Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00900302", "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 98, "start_date": "2005-04", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900302" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT00423254", "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian", "Melanoma", "Renal", "Prostate", "Colorectal", "Endometrial Carcinoma", "Cervical Carcinoma", "Testicular Cancer", "Thyroid Cancer", "Small Cell Lung Carcinoma", "Mesothelioma", "Breast Carcinoma", "Esophageal Carcinoma", "Gastric Cancer", "Pancreatic Carcinoma", "Neuroendocrine Cancer", "Liver Cancer", "Gallbladder Cancer", "Biliary Tract Cancer", "Anal Carcinoma", "Bone Sarcomas", "Soft Tissue Sarcomas", "Carcinoma of Unknown Origin, Primary" ], "interventions": [ { "name": "PSMA/PRAME", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-02", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 5, "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sparks", "state": "Nevada" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423254" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT03033576", "title": "Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Mucosal Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2017-10-23", "completion_date": "2024-03-20", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 638, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033576" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT02978625", "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Apocrine Carcinoma", "Carcinoma Arising From Cylindroma", "Carcinoma Arising From Spiradenoma", "Digital Papillary Adenocarcinoma", "Endocrine Mucin-Producing Sweat Gland Carcinoma", "Extramammary Paget Disease", "Extraocular Sebaceous Carcinoma", "Hidradenocarcinoma", "Malignant Sweat Gland Neoplasm", "Merkel Cell Carcinoma", "Microcystic Adnexal Carcinoma", "NK-Cell Lymphoma, Unclassifiable", "Papillary Adenocarcinoma", "Porocarcinoma", "Primary Cutaneous Mucinous Carcinoma", "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Merkel Cell Carcinoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Skin Squamous Cell Carcinoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Signet Ring Cell Adenocarcinoma", "Skin Adenoid Cystic Carcinoma", "Skin Adnexal Carcinoma", "Skin Basal Cell Carcinoma", "Skin Basosquamous Cell Carcinoma", "Skin Keratoacanthoma", "Skin Squamous Cell Carcinoma", "Squamoid Eccrine Ductal Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Sweat Gland Carcinoma", "Trichilemmal Carcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Mammography", "type": "PROCEDURE" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-09-27", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 36, "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978625" }, { "nct_id": "NCT01624220", "title": "A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Spinal Tumor" ], "interventions": [ { "name": "Spinal SBRT (Standard Dose)", "type": "RADIATION" }, { "name": "Spinal SBRT (Higher Dose)", "type": "RADIATION" }, { "name": "Gold Seed Implantation", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2012-08-03", "completion_date": "2023-04-14", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01624220" }, { "nct_id": "NCT01366144", "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma", "Carcinoma of Unknown Primary", "Endometrial Carcinoma", "Esophageal Carcinoma", "Liver Failure", "Lung Carcinoma", "Malignant Head and Neck Neoplasm", "Malignant Testicular Neoplasm", "Melanoma", "Metastatic Malignant Solid Neoplasm", "Ovarian Carcinoma", "Renal Failure", "Unresectable Malignant Neoplasm", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2011-06-20", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T02:12:49.626Z", "location_count": 17, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366144" } ] }